Cytokinetics, Inc. (CYTK) Posts Q4 Loss of 16c/Share; Guides FY12 Revs
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $80.01 --0%
EPS Growth %: -46.4%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -46.4%
Financial Fact:
Research and development: 19.34M
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q4 EPS of ($0.16), $0.05 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $757 thousand versus the consensus estimate of $5.62 million.
Sees FY12 revenue of $4-$5 million, versus the consensus of $4 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Sees FY12 revenue of $4-$5 million, versus the consensus of $4 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Cerebras Q1 EPS miss sends shares down 9% after-hours
- KeyBanc Upgrades Nucor (NUE) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
